 |
|
OUR PEOPLE
Adrienne M. Blanchard
Partner • Ottawa
SEARCH OUR PEOPLE
|
|
Adrienne M. Blanchard
|
|
Adrienne Blanchard is a partner is Gowlings' Ottawa office. She is vice-chair of the Firm’s Life Sciences Industry Group, and practices primarily in the areas of pharmaceutical, food, and device regulation, with a focus on compliance under the Food and Drugs Act, as well as pricing/reimbursement. Adrienne also practices in the field of intellectual property including trade-marks and life cycle management.
In the field of life sciences, Adrienne is an advocate for client interests, before regulatory bodies including Health Canada, the Patented Medicine Prices Review Board, and the Canadian Food Inspection Agency. In addition, she has appeared before Parliamentary and Senate committees on issues of concern to the innovative pharmaceutical industry
Adrienne is a frequent speaker and author on life sciences issues, and has developed an expertise in advising on the regulation of subsequent entry biologics from an innovator’s perspective.
In her intellectual property practice, Adrienne advises on life cycle issues, including patent and data package exclusivities, as well as in the field of trade-marks, advising on a full range of prosecution matters, including trade-mark searching, preparing registrability opinions, prosecuting trade-mark applications and conducting trade-mark opposition matters before the Canadian Trade-marks Office.
Adrienne joined Gowlings in 1998. She is a member of BIOTECanada’s Health Advisory Board and its Subsequent Entry Biologics Task Force. She is a member of the Intellectual Property Owners’ (IPO) Association’s Pharmaceutical and Biotechnology Issues Committee. She is also the executive editor of Drug Pricing and Reimbursement@Gowlings, an electronic newsletter published by the Firm, and was founding editor of the Gowlings publication Pharmacapsules. Adrienne is a member of the Intellectual Property Institute of Canada (IPIC), and chaired the Intellectual Property Trade Policy Committee from 1999 - 2009.
Articles and Texts
•Text: Co-editor and co-author, “Life Sciences Law in Canada” (Carswell, 2006)
•Text: Co-author, “A Practical Guide to IP Issues in the Pharmaceutical Industry” (EIPR/Sweet Maxwell, 2007)
•Article: “Health Canada Aims to Finalize its Biosimilar Pathway Guidances”, Food and Drug Law Institute, UPDATE Magazine (July 2009)
•Article: “Drug Pricing and Market Access”, Food and Drug Law Institute, UPDATE Magazine (January 2010)
Presentations
•Presentation at Gowlings U, Law Society of Upper Canada Certified CLE, Continuing Professional Development: “Life Sciences Regulatory Modernization in Canada”, (Ottawa), September 29, 2011
•Presentation at Roundtable on Safely Managing New Choices in Canada Healthcare: "Subsequent Entry Biologics: Interchangeability and Substitution in Canada and Elsewhere" (Vancouver), September 27, 2011
•Co-Chair, Canadian Institute Conference: Drug Pricing and Reimbursement (Toronto), June 14-15, 2011
•Presentation at American Conference Institute Biosimilars Conference: "Canada - Subsequent Entry Biologics" (New York), June 7-8, 2011
•Presentation at Drug Patents Insight Conference: "Subsequent Entry Biologics (SEBs)" (Toronto), May 2010
•Chair, Canadian Institute Conference: Drug Pricing and Reimbursement (Toronto), June 16-17, 2009
•Presentation at Licensing Executives Society Annual Meeting: “WTO General Council Decision on Access to Medicines” (Orlando, Florida), October 2008
•Presentation at Canadian Association of Professional Regulatory Affairs Annual Meeting: “Progressive Licensing – Legal Issues” (Ottawa), October 6, 2008
•Chair, Canadian Institute Conference: Product Life Cycle Management (Ottawa), April 2008 |
|
|
|
|
|
|
